A reagent and kit for bladder cancer diagnosis or auxiliary diagnosis

By detecting the methylation levels of five DNA regions on chromosome 1 of the human genome, a non-invasive and highly sensitive method for bladder cancer diagnosis is provided, which solves the problems of high invasiveness and low sensitivity in existing technologies, and improves the diagnostic accuracy and patient differentiation ability for bladder cancer.

CN115976213BActive Publication Date: 2024-11-29WUHAN AIMISEN LIFE TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211700726.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-29
Publication Date
2024-11-29
Estimated Expiration
2042-12-29

AI Technical Summary

Technical Problem

Current methods for bladder cancer diagnosis are highly invasive and have low sensitivity, lacking non-invasive, highly sensitive diagnostic methods.

Method used

By detecting the methylation levels of five specific DNA regions on chromosome 1 of the human genome, and using methods such as methylation-specific PCR and quantitative real-time PCR, kits are provided for the diagnosis or auxiliary diagnosis of bladder cancer.

Benefits of technology

It achieves non-invasive, highly sensitive diagnosis of bladder cancer, improves the detection rate, reduces morbidity and mortality, effectively avoids false positives, and distinguishes between bladder cancer patients and non-bladder cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115976213B_ABST
    Figure CN115976213B_ABST
Patent Text Reader

Abstract

The present application relates to a reagent and a kit for diagnosing or assisting diagnosis of bladder cancer. The reagent includes a reagent for detecting the methylation level of a target region, wherein the target region includes the full length or partial region of at least one region in Chr1:3746525-3747320, Chr1:16226730-16227150, Chr1:16227533-16228079, Chr1:63319620-63320656 and Chr1:90726838-90727252. The present application can diagnose or assist diagnosis of bladder cancer by detecting the methylation level of the target region, and has the characteristics of non-invasive, convenient and high sensitivity, and is expected to improve the detection rate of bladder cancer in my country and reduce the morbidity and mortality of the disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of molecular biology, and in particular to a reagent and a kit for diagnosing or assisting in the diagnosis of bladder cancer. Background Art

[0002] Bladder cancer is the tenth most common cancer in the world, and it is more common in men. Its incidence and mortality in the male population rank sixth and ninth in the cancer rankings, respectively. When bladder cancer is diagnosed, about 75% of patients are diagnosed with non-muscle invasive bladder cancer (NMIBC) and about 25% of patients are diagnosed with muscle invasive bladder cancer (MIBC). There are significant differences in the treatment methods and clinical outcomes for NMIBC and MIBC. NMIBC usually does not invade the bladder muscle layer, and the prognosis is relatively good. It can be treated with transurethral electroresection, but it is prone to recurrence and there is a possibility of developing into MIBC. MIBC usually invades the bladder muscle layer, and patients need radical cystectomy for treatment, and need to perform corresponding chemotherapy regimens according to the pathological characteristics of the tumor. For patients with advanced bladder cancer who have already metastasized, the survival rate is less than 5%. Therefore, early diagnosis and early treatment of bladder cancer patients are key ways to improve their quality of life and life cycle.

[0003] Currently, the commonly used methods for diagnosing bladder cancer in clinical practice include: cystoscopy, urine exfoliated cytology, fluorescence in situ hybridization (FISH), etc. Cystoscopy and pathological biopsy are the gold standard for diagnosing bladder cancer, but as invasive examinations, patients need to be anesthetized, and there are risks such as urethral perforation and urethral infection, which leads to high pain and low acceptance of patients. Urine exfoliated cytology and fluorescence in situ hybridization are non-invasive operations with good specificity for diagnosing bladder cancer, but these two methods have low diagnostic sensitivity for early non-muscle invasive cancer, and their diagnostic accuracy depends on the physician's diagnostic experience. Therefore, there is an urgent need for non-invasive, convenient, and highly sensitive methods for diagnosing bladder cancer.

[0004] A common feature of bladder cancer is the change in the epigenetic mechanism of cancer cells. Epigenetics refers to the heritable changes in gene function without changing the DNA sequence of the gene, which ultimately leads to phenotypic changes. DNA methylation, histone variation, chromatin remodeling and histone post-translational modification are the main epigenetic mechanisms that affect gene expression. In general, in the genome of cancer cells, the degree of DNA methylation is reduced, which contributes to the overexpression of proto-oncogenes and the increase in mutation rate; at the same time, the DNA in the promoter region of its tumor suppressor gene will be highly methylated, thereby inhibiting the expression of tumor suppressor genes, which is conducive to tumor invasion, metastasis and angiogenesis. Therefore, abnormal DNA methylation may serve as a molecular marker for the diagnosis, prognosis and treatment of bladder cancer. Summary of the invention

[0005] Based on this, in order to solve the problem that there is currently no highly sensitive and non-invasive method for diagnosing or assisting in the diagnosis of bladder cancer, it is necessary to provide a reagent and kit for diagnosing or assisting in the diagnosis of bladder cancer.

[0006] The specific technical solutions are as follows:

[0007] A reagent for diagnosing or assisting in the diagnosis of bladder cancer, the reagent comprising a reagent for detecting the methylation level of a target region, the target region comprising the full length or a partial region of at least one of the following regions: region 1, region 2, region 3, region 4, and region 5;

[0008] Among them, GRCh38.p14 is used as the reference genome, the region 1 is Chr1:3746525-3747320, the region 2 is Chr1:16226730-16227150, the region 3 is Chr1:16227533-16228079, the region 4 is Chr1:63319620-63320656, and the region 5 is Chr1:90726838-90727252.

[0009] In one embodiment, the partial area of ​​region 1 includes one or more of region 1-1, region 1-2, region 1-3, region 1-4 and region 1-5; the region 1-1 is Chr1:3746525-3746671, the region 1-2 is Chr1:3746695-3746839, the region 1-3 is Chr1:3746854-3746987, the region 1-4 is Chr1:3747021-3747165, and the region 1-5 is Chr1:3747172-3747320.

[0010] In one embodiment, the partial area of ​​region 2 includes one or more of region 2-1, region 2-2, region 2-3 and region 2-4; the region 2-1 is Chr1:16226730-16226856, the region 2-2 is Chr1:16226858-16226981, the region 2-3 is Chr1:16226949-16227062, and the region 2-4 is Chr1:16227037-16227150.

[0011] In one embodiment, the partial area of ​​region 3 includes one or more of region 3-1, region 3-2, region 3-3 and region 3-4; the region 3-1 is Chr1: 16227533-16227709, the region 3-2 is Chr1: 16227656-16227788, the region 3-3 is Chr1: 16227829-16227969, and the region 3-4 is Chr1: 16227983-16228079.

[0012] In one embodiment, the partial area of ​​region 4 includes one or more of region 4-1, region 4-2, region 4-3, region 4-4, region 4-5 and region 4-6; the region 4-1 is Chr1:63319620-63319777, the region 4-2 is Chr1:63319748-63319883, the region 4-3 is Chr1:63319927-63320117, the region 4-4 is Chr1:63320163-63320286, the region 4-5 is Chr1:63320290-63320419, and the region 4-6 is Chr1:63320525-63320656.

[0013] In one embodiment, the partial area of ​​region 5 includes one or more of region 5-1 and region 5-2; the region 5-1 is Chr1:90727082-90727252; the region 5-2 is Chr1:90726838-90726994.

[0014] In one embodiment, the target area includes at least two of area 1, area 2, area 3, area 4 and area 5.

[0015] In one embodiment, the target area includes at least two of a partial area of ​​area 1, a partial area of ​​area 2, a partial area of ​​area 3, a partial area of ​​area 4, and a partial area of ​​area 5.

[0016] In one embodiment, the reagent detects methylation of the target region by one or more of the following methods: methylation-specific PCR, methylation-specific fluorescent quantitative PCR, bisulfite sequencing, methylation-specific microarray, whole genome bisulfite sequencing, pyrophosphate sequencing, methylation-specific high performance liquid chromatography, digital PCR, methylation-specific high resolution melting curve method, methylation-sensitive restriction endonuclease method.

[0017] In one embodiment, the reagent comprises a nucleic acid molecule.

[0018] In one embodiment, the nucleic acid molecule includes a nucleic acid combination of a detection primer pair and a corresponding detection probe for detecting the methylation level of the full length or a portion of at least one of the following regions: region 1, region 2, region 3, region 4 and region 5.

[0019] In one embodiment, the detection primer pair and corresponding detection probe for detecting the methylation level of the full length or a part of the region 1 include at least one group of the nucleic acid combinations shown in SEQ ID NO.16-18, SEQ ID NO.19-21, SEQ ID NO.22-24, SEQ ID NO.25-27 and SEQ ID NO.28-30; the detection primer pair and corresponding detection probe for detecting the methylation level of the full length or a part of the region 2 include at least one group of the nucleic acid combinations shown in SEQ ID NO.31-33, SEQ ID NO.34-36, SEQ ID NO.37-39 and SEQ ID NO.40-42; the detection primer pair and corresponding detection probe for detecting the methylation level of the full length or a part of the region 3 include at least one group of the nucleic acid combinations shown in SEQ ID NO.43-45, SEQ ID NO.46-48, SEQ ID NO.49-51 and SEQ ID NO.52-54; the detection primer pair and corresponding detection probe for detecting the methylation level of the full length or a part of the region 4 include SEQ ID NO. At least one of the nucleic acid combinations shown in SEQ ID NO.55-57, SEQ ID NO.58-60, SEQ ID NO.61-63, SEQ ID NO.64-66, SEQ ID NO.67-69 and SEQ ID NO.70-72; and / or, the detection primer pairs and corresponding detection probes for detecting the methylation level of the full length or partial region of region 5 include at least one of the nucleic acid combinations shown in SEQ ID NO.73-75 and SEQ ID NO.76-78.

[0020] In one embodiment, the reagent includes a reagent that can differentially modify methylated DNA and unmethylated DNA.

[0021] Optionally, the reagent is bisulfite.

[0022] A kit for diagnosing or assisting diagnosis of bladder cancer, comprising any of the reagents described above.

[0023] Use of any of the above reagents in the preparation of bladder cancer diagnosis or auxiliary diagnosis products.

[0024] Compared with the prior art, this application has the following beneficial effects:

[0025] The present application discovered that by using at least one of the five DNA regions on chromosome 1 in the human genome as a molecular marker and detecting the methylation level of the molecular marker, bladder cancer can be diagnosed or assisted in diagnosis. The molecular marker provided by the present application has the characteristics of being non-invasive, convenient, and highly sensitive, and is expected to improve the detection rate of bladder cancer in my country and reduce the incidence and mortality of the disease.

[0026] The kit provided in this application can perform diagnosis quickly, efficiently and accurately, effectively avoid false positives caused by interference from other diseases of the urinary system, and help distinguish bladder cancer patients from non-bladder cancer patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The average methylation levels of the corresponding probes in the molecular markers in bladder cancer tissues and adjacent normal tissues. DETAILED DESCRIPTION

[0028] In order to facilitate understanding of the present application, the present application will be described more fully below. However, the present application can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the present application disclosure more thorough and comprehensive.

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0030] Explanation of terms

[0031] The term "and / or" is intended to include any and all combinations of one or more of the associated listed items.

[0032] The term "plurality" means more than two; "multiple" means more than two; and "above" when combined with a number to express a quantity includes the number itself, for example "more than two" includes two.

[0033] The term "diagnosis" includes auxiliary diagnosis, recurrence risk assessment, assessment of cancer risk and degree, and prognosis.

[0034] The term "oligonucleotide" or "polynucleotide" or "nucleotide" or "nucleic acid" refers to a molecule having two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. Oligonucleotides can be produced in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof. The typical deoxyribonucleotides of DNA are thymine, adenine, cytosine, and guanine. The typical ribonucleotides of RNA are uracil, adenine, cytosine, and guanine.

[0035] The term "methylation" is a form of chemical modification of DNA that can change genetic expression without changing the DNA sequence. DNA methylation refers to the covalent attachment of a methyl group to the 5th carbon position of cytosine in genomic CpG dinucleotides under the action of DNA methyltransferase. DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability, and the way DNA interacts with proteins, thereby controlling gene expression.

[0036] The term "methylation level" refers to whether the cytosine in one or more CpG dinucleotides in a DNA sequence is methylated, or the frequency / proportion / percentage of methylation, which represents both qualitative and quantitative concepts. In practical applications, different detection indicators can be used to compare DNA methylation levels according to actual conditions. For example, in some cases, the comparison can be made based on the Ct value of the sample test; in some cases, the proportion of gene methylation in the sample can be calculated, that is, the number of methylated molecules / (the number of methylated molecules + the number of unmethylated molecules) × 100%, and then compared; in some cases, it is also necessary to statistically analyze and integrate the various indicators to obtain the final judgment indicator.

[0037] The term "primer" refers to an oligonucleotide that can be used in an amplification method (e.g., polymerase chain reaction, PCR) to amplify a target sequence based on a polynucleotide sequence corresponding to a target gene or a portion thereof. Typically, at least one of the PCR primers used to amplify a polynucleotide sequence is sequence-specific for the polynucleotide sequence. The exact length of the primer depends on many factors, including temperature, primer source, and the method used. For example, for diagnostic and prognostic applications, oligonucleotide primers typically contain at least 10, 15, 20, 25 or more nucleotides, but may also contain fewer nucleotides, depending on the complexity of the target sequence. In the disclosure herein, the term "primer" refers to a pair of primers that can hybridize with the double strands of a target DNA molecule or can hybridize with a region of a target DNA molecule that is located on both sides of the nucleotide sequence to be amplified.

[0038] The term "methylation-specific PCR" is one of the most sensitive experimental techniques for studying methylation, and can detect methylation in as little as about 50 pg of DNA. After single-stranded DNA is converted by bisulfite, all unmethylated cytosines are deaminated and converted to uracil, while methylated cytosines in CpG sites remain unchanged. Therefore, two pairs of primers for methylated and unmethylated sequences are designed respectively, and methylated and unmethylated DNA sequences can be distinguished by PCR amplification. In the disclosure of this article, methylation primers are added when performing real-time quantitative methylation-specific PCR. If the Ct value meets the requirements (for example, Ct≤38 in tissue samples), it indicates that the target sequence is methylated.

[0039] The term "methylation-specific fluorescent quantitative PCR (q-MSP)" is an experimental technique that combines fluorescent quantitative PCR technology with methylation-specific PCR technology. This technology is also based on the sequence differences of DNA in different methylation states after bisulfite conversion to design appropriate primer pairs, thereby distinguishing methylated and unmethylated sequences, but the final detection indicator of q-MSP is the fluorescent signal. Therefore, in the q-MSP reaction system, in addition to adding methylation detection primers, fluorescent probes or fluorescent dyes are also required. Compared with traditional methylation-specific PCR technology, q-MSP has higher sensitivity and specificity in detecting DNA methylation levels, and is more suitable for detecting trace amounts of abnormally methylated DNA fragments mixed in the DNA of early cancer patients. This technology does not require gel electrophoresis detection and is easier to operate.

[0040] The term "TaqMan probe" refers to an oligonucleotide sequence containing a 5' fluorescent group and a 3' quencher group. When the probe binds to the corresponding site on the DNA, the probe will not emit fluorescence because of the presence of a quencher group near the fluorescent group. During the amplification process, if the probe binds to the amplified chain, the 5'-3' exonuclease activity of the DNA polymerase (such as Taq enzyme) will digest the probe, and the fluorescent group will be away from the quencher group, and its energy will not be absorbed, thus generating a fluorescent signal. After each PCR cycle, the fluorescent signal also has a synchronous exponential growth process like the target fragment.

[0041] One embodiment of the present application provides a reagent for diagnosing or assisting in the diagnosis of bladder cancer, the reagent comprising a reagent for detecting the methylation level of a target region, the target region comprising the full length or a partial region of at least one of the following regions: region 1, region 2, region 3, region 4, and region 5;

[0042] Among them, region 1 is Chr1:3746525-3747320, region 2 is Chr1:16226730-16227150, region 3 is Chr1:16227533-16228079, region 4 is Chr1:63319620-63320656, and region 5 is Chr1:90726838-90727252.

[0043] It should be noted that, in this article, unless otherwise specified, the position on the chromosome is based on GRCh38.p14. In addition, because the DNA on the chromosome is a double-stranded structure consisting of a positive strand and a negative strand, for a region represented by a chromosome position, if it is not specified whether it is a positive strand or a negative strand of DNA, it means that it can be the positive strand of the DNA in the region, it can also be the negative strand of the DNA in the region, or it can be both the positive and negative strands of the DNA in the region.

[0044] In a specific example, region 1 is the positive strand of Chr1:3746525-3747320, region 2 is the positive strand of Chr1:16226730-16227150, region 3 is the positive strand of Chr1:16227533-16228079, region 4 is the positive strand of Chr1:63319620-63320656, and region 5 is the negative strand of Chr1:90726838-90727252.

[0045] In a specific example, the target area includes at least two of the full length or part of area 1, the full length or part of area 2, the full length or part of area 3, the full length or part of area 4, and the full length or part of area 5.

[0046] In a specific example, the target area includes at least two of a partial area of ​​area 1 , a partial area of ​​area 2 , a partial area of ​​area 3 , a partial area of ​​area 4 , and a partial area of ​​area 5 .

[0047] In a specific example, the partial region of region 1 includes one or more of region 1-1, region 1-2, region 1-3, region 1-4 and region 1-5; wherein region 1-1 is Chr1:3746525-3746671; region 1-2 is Chr1:3746695-3746839; region 1-3 is Chr1:3746854-3746987; region 1-4 is Chr1:3747021-3747165; region 1-5 is Chr1:3747172-3747320. In other examples, the partial region of region 1 also includes other unlisted DNA fragments located between Chr1:3746525-3747320.

[0048] In a specific example, the partial region of region 2 includes one or more of region 2-1, region 2-2, region 2-3 and region 2-4; wherein region 2-1 is Chr1:16226730-16226856; region 2-2 is Chr1:16226858-16226981; region 2-3 is Chr1:16226949-16227062; and region 2-4 is Chr1:16227037-16227150. In other examples, the partial region of region 2 also includes other unlisted DNA fragments located between Chr1:16226730-16227150.

[0049] In a specific example, the partial region of region 3 includes one or more of region 3-1, region 3-2, region 3-3 and region 3-4; wherein region 3-1 is Chr1:16227533-16227709; region 3-2 is Chr1:16227656-16227788; region 3-3 is Chr1:16227829-16227969; and region 3-4 is Chr1:16227983-16228079. In other examples, the partial region of region 3 also includes other unlisted DNA fragments located between Chr1:16227533-16228079.

[0050] In a specific example, the partial region of region 4 includes one or more of region 4-1, region 4-2, region 4-3, region 4-4, region 4-5 and region 4-6; wherein region 4-1 is Chr1:63319620-63319777; region 4-2 is Chr1:63319748-63319883; region 4-3 is Chr1:63319927-63320117; region 4-4 is Chr1:63320163-63320286; region 4-5 is Chr1:63320290-63320419; and region 4-6 is Chr1:63320525-63320656. In other examples, the partial region of region 4 also includes other unlisted DNA fragments located between Chr1:63319620-63320656.

[0051] In a specific example, the partial region of region 5 includes one or more of region 5-1 and region 5-2, wherein region 5-1 is Chr1:90727082-90727252, and region 5-2 is Chr1:90726838-90726994. In other examples, the partial region of region 5 also includes other unlisted DNA fragments located between Chr1:90726838-90727252.

[0052] In a specific example, the target area includes at least one of area 1-1, area 1-2, area 1-3, area 1-4, area 1-5, area 2-1, area 2-2, area 2-3, area 2-4, area 3-1, area 3-2, area 3-3, area 3-4, area 4-1, area 4-2, area 4-3, area 4-4, area 4-5, area 4-6, area 5-1 and area 5-2.

[0053] In a specific example, the target area includes at least two of area 1-1, area 1-2, area 1-3, area 1-4, area 1-5, area 2-1, area 2-2, area 2-3, area 2-4, area 3-1, area 3-2, area 3-3, area 3-4, area 4-1, area 4-2, area 4-3, area 4-4, area 4-5, area 4-6, area 5-1 and area 5-2.

[0054] In a specific example, the target area includes any two combinations of area 1-4, area 2-2, area 3-1, area 4-5, and area 5-1.

[0055] Considering that urine is an extremely easy-to-obtain body fluid sample, tumor cells in urinary system tumor tissues will continuously fall off and be excreted from the body with urine, and the genetic information carried by the exfoliated cells in the urine sample is consistent with the in situ tissue, the inventor believes that the genomic DNA of the exfoliated cells in the urine sample can reflect the pathological characteristics of the urinary system to a certain extent. In this application, the sensitivity of diagnosing urine samples of bladder cancer patients by detecting the methylation level of the combination of two target regions can reach 93%, and the specificity of diagnosing urine samples of patients with benign urinary system diseases can reach 97.67%, and the specificity of diagnosing urine samples of healthy people can reach 100%, thereby effectively distinguishing bladder cancer patients from non-bladder cancer patients.

[0056] In a specific example, the reagent detects methylation of the target region by one or more of the following methods: methylation-specific PCR, methylation-specific fluorescent quantitative PCR, bisulfite sequencing, methylation-specific microarray, whole genome bisulfite sequencing, pyrophosphate sequencing, methylation-specific high-performance liquid chromatography, digital PCR, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method.

[0057] In one particular example, the reagent includes a nucleic acid molecule.

[0058] In a specific example, the nucleic acid molecule includes a detection primer pair and / or a corresponding detection probe for detecting the methylation level of the full length or a partial region of at least one of the following regions. The primer pairs and detection probes of the present application are not particularly limited. After determining that the above-mentioned region is the detection target region for diagnosing bladder cancer, those skilled in the art can design specific primer pairs and detection probes according to methods and tools known in the art, as long as the purpose of detecting the methylation level of the target region can be achieved.

[0059] In a specific example, the primer pair for detecting the methylation level of region 1 includes at least one of the primer pairs shown in SEQ ID NOs. 16 to 17, the primer pairs shown in SEQ ID NOs. 19 to 20, the primer pairs shown in SEQ ID NOs. 22 to 23, the primer pairs shown in SEQ ID NOs. 25 to 26, and the primer pairs shown in SEQ ID NOs. 28 to 29; the primer pair for detecting the methylation level of region 2 includes at least one of the primer pairs shown in SEQ ID NOs. 31 to 32, the primer pairs shown in SEQ ID NOs. 34 to 35, the primer pairs shown in SEQ ID NOs. 37 to 38, and the primer pairs shown in SEQ ID NOs. 40 to 41; the primer pair for detecting the methylation level of region 3 includes at least one of the primer pairs shown in SEQ ID NOs. 43 to 44, the primer pairs shown in SEQ ID NOs. 46 to 47, the primer pairs shown in SEQ ID NOs. 49 to 50, and the primer pairs shown in SEQ ID NOs. 52 to 53; the primer pair for detecting the methylation level of region 4 includes at least one of the primer pairs shown in SEQ ID NOs. The invention further comprises at least one of the primer pairs shown in SEQ ID NOs. 55 to 56, the primer pairs shown in SEQ ID NOs. 58 to 59, the primer pairs shown in SEQ ID NOs. 61 to 62, the primer pairs shown in SEQ ID NOs. 64 to 65, the primer pairs shown in SEQ ID NOs. 67 to 68, and the primer pairs shown in SEQ ID NOs. 70 to 71; and / or the primer pairs for detecting the methylation level of region 5 include at least one of the primer pairs shown in SEQ ID NOs. 73 to 74 and the primer pairs shown in SEQ ID NOs. 76 to 77.

[0060] In a specific example, the detection probe for detecting the methylation level of region 1 includes at least one of the detection probes shown in SEQ ID NO.18, SEQ ID NO.21, SEQ ID NO.24, SEQ ID NO.27 and SEQ ID NO.30; the detection probe for detecting the methylation level of region 2 includes at least one of the probes shown in SEQ ID NO.33, SEQ ID NO.36, SEQ ID NO.39 and SEQ ID NO.42; the detection probe for detecting the methylation level of region 3 includes at least one of the probes shown in SEQ ID NO.45, SEQ ID NO.48, SEQ ID NO.51 and SEQ ID NO.54; the detection probe for detecting the methylation level of region 4 includes at least one of the probes shown in SEQ ID NO.57, SEQ ID NO.60, SEQ ID NO.63, SEQ ID NO.66, SEQ ID NO.69 and SEQ ID NO.72; and / or the detection probe for detecting the methylation level of region 5 includes at least one of the probes shown in SEQ ID NO.75 and SEQ ID NO.78.

[0061] In a specific example, the reagent includes a reagent that can differentially modify methylated DNA and non-methylated DNA. Optionally, the reagent is bisulfite.

[0062] One embodiment of the present application also provides a kit for diagnosing or assisting in the diagnosis of bladder cancer, comprising any of the reagents described above.

[0063] In a specific example, the kit also includes at least one of a PCR amplification reagent, a nucleic acid extraction reagent, a nucleic acid purification reagent, and a sample sampling device.

[0064] In a specific example, the samples detected by the kit include but are not limited to tissues, blood, urine, etc.

[0065] One embodiment of the present application also provides the use of a reagent for detecting the methylation level of a target region in the preparation of a product for bladder cancer diagnosis or auxiliary diagnosis, wherein the target region includes any of the target regions described above.

[0066] The bladder cancer diagnosis or auxiliary diagnosis of the present application includes distinguishing bladder cancer patients from healthy people, or includes distinguishing bladder cancer patients from patients with benign urinary system diseases. Specific embodiments

[0068] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0069] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0070] Example 1 Selection of molecular markers

[0071] The DNA methylation data of bladder cancer were downloaded from the TCGA database. After merging, sorting and correction, the methylation levels of each probe in adjacent normal tissues and cancer tissues were analyzed to find probes with a methylation level (β value) higher than 0.4 in bladder cancer tissues and a methylation level (β value) lower than 0.2 in adjacent normal tissues, and with a statistically significant difference (P < 0.05) in the methylation levels of adjacent normal tissues and cancer tissues. The methylation sites recognized by each probe that met the conditions were analyzed, and it was found that the probes could recognize 5 regions in chromosome 1 of the human genome, namely region 1, region 2, region 3, region 4 and region 5. The average methylation levels of the probes that recognized the 5 DNA regions in bladder cancer tissues and adjacent normal tissues are shown in Figure 2. Figure 1 As shown, the methylation levels of all probes in cancer tissues were significantly higher than those in adjacent normal tissues. The specific locations and DNA sequences of the five DNA regions in the genome (with GRCh38.p14 as a reference) are shown in Table 1.

[0072] Table 1 Physical location of molecular markers

[0073]

[0074] Accordingly, the five DNA regions shown in Table 1 were selected as potential molecular markers for diagnosing or assisting in the diagnosis of bladder cancer urine samples, and were named Marker Ⅰ, Marker Ⅱ, Marker Ⅲ, Marker Ⅳ and Marker Ⅴ, respectively.

[0075] Example 2 Methylation detection method for 5 molecular markers

[0076] In order to achieve the purpose of simply and quickly performing simultaneous detection of multiple samples, this embodiment provides a method for detecting the methylation levels of five molecular markers in the sample to be tested based on methylation-specific fluorescent quantitative PCR.

[0077] First, methylation detection primer pairs and detection probes were designed based on the template. Methyl Primer Express software was used to obtain DNA sequences that were completely methylated and converted by bisulfite, as shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, and SEQ ID NO.5, which were SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10, respectively; in addition, all C bases in the DNA sequences of SEQ ID NO.1 to SEQ ID NO.5 were replaced with T bases, respectively, to obtain DNA sequences that were completely unmethylated and converted by bisulfite, as SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13, SEQ ID NO.14, and SEQ ID NO.15, respectively. SEQ ID NO.6 to SEQ ID NO.15 were artificially synthesized and constructed into plasmid vectors, respectively, as templates for primer pair screening.

[0078] Using the DNA sequences shown in SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10 as templates, methylation detection primer pairs and detection probes for Marker I, Marker II, Marker III, Marker IV and Marker V were designed. The designed methylation detection primer pairs and detection probes were artificially synthesized, and the above artificially constructed plasmids were used as templates to perform qPCR experiments to detect the sensitivity and specificity of the primer pairs in amplifying the target region. In addition to meeting the requirements of conventional primer design, the methylation primer pairs used to detect the five molecular markers must also meet the following conditions: 1) The amplification efficiency of the methylation primer pairs for the target region is about 100%, which must be more than 90% and less than 110%. Therefore, in order to improve the amplification efficiency of methylation fluorescence quantitative PCR, the amplicons amplified by the methylation primer pairs for the five molecular markers do not exceed 200bp; 2) When the methylated plasmid template and the non-methylated plasmid template are added to the PCR system at the same time, the methylated primer pairs only amplify the methylated plasmid template, and do not amplify the non-methylated plasmid template. After screening, the sequences of the detection primer pairs and detection probes for detecting the methylation levels of each target region of the five molecular markers are shown in Table 2.

[0079] Table 2 Methylation detection primer pairs and detection probes

[0080]

[0081]

[0082]

[0083] The detection probes provided in Table 1 are all TaqMan probes, whose 5' ends are connected to fluorescent groups, such as FAM, ROX, VIC, CY5, etc., and whose 3' ends are connected to fluorescent quenching groups, such as BHQ, BHQ1, MGB, etc. The DNA region corresponding to the amplicon that can be amplified by each pair of methylation detection primers is called the target region. The methylation levels of 5 different DNA regions (target regions) in region 1 can be detected by the 5 pairs of methylation detection primers and detection probes for Marker I, and other methylation detection primer pairs and detection probes can also detect the methylation levels of different DNA regions (target regions) in each molecular marker. Specifically, the physical location of the DNA region (target region) detectable by each pair of methylation detection primers and detection probes and the methylated cytosine sites that can be detected are shown in Table 3.

[0084] Table 3 Target regions and cytosine sites detected by methylation detection primer pairs and detection probes

[0085]

[0086]

[0087]

[0088] After the synthetic plasmid was used as a template for qPCR reaction to screen the methylation detection primer pair and the detection probe, the transformed bladder cancer cell line HTB9 genomic DNA and the transformed human leukocyte genomic DNA were used as templates to detect the performance of the methylation primer pair in amplifying the target region. At this time, the amplification primer pair and the detection probe of the internal reference gene ACTB need to be added to the amplification system to monitor the sample quality. The sequences of the upstream primer, downstream primer and detection probe for amplifying the ACTB gene are respectively

[0089] 5'-AAGGGTGGTTGGGTGGTTGTTTTG-3' (SEQ ID NO.79),

[0090] 5'-AATAACACCCCCACCCTGC-3' (SEQ ID NO.80),

[0091] 5'-GGAGTGGTTTTTGGGTTTG (SEQ ID NO. 81).

[0092] After verification, when the transformed bladder cancer cell HTB9 genomic DNA is used as a template, the amplification efficiency of the methylation detection primer pair and the detection probe provided in Table 1 is between 90% and 110%, and when the transformed human leukocyte genomic DNA is used as a template, the amplification specificity of the methylation detection primer pair and the detection probe provided in Table 1 is higher than 90%. The above shows that the primers and probes provided in Table 1 can be used for the detection of the methylation levels of MarkerⅠ, MarkerⅡ, MarkerⅢ, MarkerⅣ and MarkerⅤ.

[0093] Example 3 Detection performance of single molecule markers in urine samples

[0094] 1. Sample collection:

[0095] 100 urine samples were collected from patients diagnosed with bladder cancer by pathological tissue testing, and 40 urine samples were collected from healthy people. In addition, 86 urine samples were collected from patients with common benign urinary system diseases (cystitis glandularis, urinary tract infection, prostatic hyperplasia, kidney stones, hydronephrosis, etc.), and the volume of each urine sample collected was greater than 50mL. The collection process of all samples was approved by the ethics committee, all volunteers signed informed consent forms, and all samples were anonymized.

[0096] 2. Extraction of DNA from urine samples:

[0097] The nucleic acid extraction kit of Wuhan Aimisen Life Science Technology Co., Ltd. (Ehan Equipment No. 20210740) was used to extract DNA from urine samples, and the specific operations were carried out according to the instructions of the kit.

[0098] 3.Conversion and purification of urine sample DNA:

[0099] Use the nucleic acid conversion reagent (Ehan Medical No. 20200843) of Wuhan Aimeisen Life Science Technology Co., Ltd. to convert and purify the DNA of urine samples. For specific operation steps, please refer to the kit instructions.

[0100] 4. Methylation-specific fluorescence quantitative PCR reaction:

[0101] The transformed and purified sample DNA was used as a template, and the methylation detection primer pairs and probes provided in Table 1 were used to perform MSP reaction to detect the methylation level of the target region in the sample to be tested. For a certain sample to be tested, in the PCR reaction system as shown in Table 4, it is necessary to add the DNA extracted, transformed and purified from the sample, the primer pairs and probes for detecting a certain target region, the detection primer pairs and probes of the internal reference gene ACTB, as well as Taq enzyme and corresponding PCR buffer. Subsequently, the amplification reaction was performed according to the qPCR program, and the reaction conditions were: 98°C pre-denaturation for 10min; 95°C denaturation for 30s, 60°C annealing for 30s, 72°C supplementary extension for 5min (collecting fluorescence during annealing and supplementary extension), a total of 47 cycles; 4°C storage. In this embodiment, the fluorescent groups at the 5' end of the detection probe of the target region are all FAM, and the fluorescent quenching groups at the 3' end are all MGB, the fluorescent group at the 5' end of the ACTB gene detection probe is ROX, and the fluorescent quenching group at the 3' end is BHQ.

[0102] Table 4 PCR system

[0103]

[0104]

[0105] In addition, positive and negative controls need to be set up separately during PCR amplification. When amplifying a target region, the template of the positive control PCR tube is a plasmid containing the target region and a plasmid containing the transformed ACTB gene, and the rest is the same as the experimental tube; the template of the negative control PCR tube is ultrapure water, and the rest of the system and reaction procedures are the same as the experimental tube. After the PCR is completed, samples that failed to be tested are eliminated according to the requirements of quality control, and the Ct value of qualified samples is read. The quality control standards are: 1) The negative control tube does not produce lines and there is no amplification; 2) The amplification curve of the positive control tube is S-shaped, and the Ct values ​​of all genes are between 25-30; 3) The Ct value of the reference gene in the experimental tube is less than or equal to 33.

[0106] 5. Result determination:

[0107] In the sample to be tested, if the Ct value of the amplified target region is less than or equal to 38, the target region in this sample is considered to be methylation-positive, and the sample is a cancer-positive sample; if the Ct value of the amplified target region is greater than 38, the target region in this sample is considered to be methylation-negative, and the sample is a cancer-negative sample. According to the above judgment criteria, the performance of using the methylation levels of 21 target regions in 5 molecular markers to diagnose some urine samples is shown in Table 5. Some samples in Table 5 include 60 urine samples from patients with bladder cancer, 43 urine samples from patients with benign urinary system diseases, and 40 urine samples from healthy people. In Table 5, the sensitivity is the proportion of urine samples of patients with pathological positives that are judged as positive by the MSP method, and the specificity is the proportion of urine samples of patients with benign urinary system diseases and healthy people that are judged as negative by the MSP method.

[0108] Table 5 Performance of single molecule markers in diagnosing urine samples

[0109]

[0110]

[0111] As can be seen from Table 5, Marker I, Marker II, Marker III, Marker IV and Marker V all have good diagnostic effects for bladder cancer patients. Overall, the sensitivity of diagnosing urine samples of bladder cancer patients by detecting the methylation levels of the 21 target regions of the 5 molecular markers is 66.67% to 85.00%, the specificity of detecting urine samples of patients with benign urinary system diseases is 81.40% to 97.67%, and the specificity of detecting urine samples of healthy people is 95% to 100%. In addition, the specificity of the 21 target regions of the 5 molecular markers in detecting urine samples is better than the sensitivity of detecting urine samples. Specifically, for Marker Ⅰ, region 1-3 has the highest sensitivity in detecting urine samples from cancer patients, which can reach 78.33%, while region 1-4 has the highest specificity in detecting urine samples from healthy people and patients with benign urinary system diseases, which are 100% and 90.70%, respectively; for Marker Ⅱ, region 2-1 and region 2-3 have the highest sensitivity in detecting urine samples from cancer patients, which are both 83.33%, while region 2-2 has the highest specificity in detecting urine samples from healthy people and patients with benign urinary system diseases, which are 100% and 95.35%, respectively; for Marker Ⅲ, region 3-3 has the highest sensitivity in detecting urine samples from cancer patients, which can reach 78.33 %, while area 3-1 has the highest specificity in detecting urine samples from healthy people and patients with benign urinary system diseases, which are 100% and 97.67% respectively; for Marker Ⅳ, area 4-2 has the highest sensitivity in detecting urine samples from cancer patients, which can reach 85.00%, while area 4-5 has the highest specificity in detecting urine samples from healthy people and patients with benign urinary system diseases, which are 100% and 97.67% respectively; for Marker Ⅴ, area 5-2 has the highest sensitivity in detecting urine samples from cancer patients, which can reach 81.67%, while area 5-1 has the highest specificity in detecting urine samples from healthy people and patients with benign urinary system diseases, which are 100% and 93.02% respectively.

[0112] Example 4 Detection performance of dual molecular markers in urine samples

[0113] As can be seen from Table 5, the 5 molecular markers with a total of 21 target regions have good specificity in detecting urine samples of healthy people and patients with benign urinary system diseases. Therefore, it is possible to consider diagnosing bladder cancer by detecting the methylation level of the dual molecular markers to further improve the sensitivity of detecting bladder cancer urine samples. The target regions with the best specificity among the 5 molecular markers are selected as representatives to analyze the performance of the marker combination in detecting urine samples, wherein region 1-4 represents Marker I, region 2-2 represents Marker II, region 3-1 represents Marker III, region 4-5 represents Marker IV, and region 5-1 represents Marker V. First, the Ct values ​​of the above 5 target regions in urine samples of all 100 patients with bladder cancer, urine samples of 40 healthy people, and urine samples of 86 patients with benign urinary system diseases are detected using the methods provided in Examples 2 and 3. Then, the methylation levels of any two of the five target regions in each urine sample are analyzed to determine whether the sample is positive for bladder cancer. The specific criteria are: 1) If the Ct value of at least one of the two target regions in a sample is less than or equal to 38, that is, at least one of the two target regions in the sample is positive for methylation, and the sample is a positive sample for bladder cancer; 2) If the Ct values ​​of the two target regions in a sample are both greater than 38, that is, the two target regions in the sample are negative for methylation, and the sample is a negative sample for bladder cancer. According to the above criteria, the performance of the combination of any two of the five representative target regions in diagnosing urine samples of bladder cancer patients is shown in Table 6.

[0114] Table 6 Detection performance of dual molecular markers in urine samples

[0115]

[0116]

[0117] As can be seen from Table 6, when the methylation levels of the two marker combinations are detected, the sensitivity of diagnosing bladder cancer patients is significantly improved, while the specificity is not significantly reduced. Therefore, the combined diagnosis of two markers is better than the single marker diagnosis. Overall, the sensitivity of any two marker combinations of the five molecular markers to diagnose urine samples of bladder cancer patients ranges from 78% to 93%, and the specificity of diagnosing urine samples of patients with benign urinary system diseases ranges from 86.05% to 97.67%, and the specificity of diagnosing urine samples of healthy people is 100%. Specifically, the marker combinations Markers Ⅰ+Ⅳ and Markers Ⅱ+Ⅳ have the highest sensitivity for diagnosing urine samples of bladder cancer patients, both of which are 93%, and the marker combination Markers Ⅲ+Ⅳ has the highest specificity for diagnosing patients with benign urinary system diseases, which is 97.67%. In addition, it can be seen that the marker combinations Markers Ⅱ+Ⅳ and Markers Ⅲ+Ⅳ have the best diagnostic performance.

[0118] In summary, by detecting the DNA methylation levels of 21 different target regions in the five molecular markers on chromosome 1, bladder cancer patients and non-bladder cancer patients can be effectively distinguished, and the diagnosis method of any two markers in combination among the five molecular markers is better than single marker diagnosis. The samples tested by the above diagnostic method are all urine samples, and the detection sensitivity can reach 93% and the specificity can reach 97.67%, which is good news for bladder cancer patients.

[0119] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0120] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims, and the description and drawings may be used to interpret the contents of the claims.

Claims

1. A reagent for diagnosing or assisting in the diagnosis of bladder cancer, characterized in that: The reagents include primer pairs with nucleotide sequences as shown in SEQ ID NOs.34-35 and SEQ ID NOs.67-68, and probes with nucleotide sequences as shown in SEQ ID NOs.36 and SEQ ID NO.

69.

2. The reagent according to claim 1, characterized in that The reagent performs methylation detection by methylation-specific fluorescent quantitative PCR.

3. The reagent according to claim 1 or 2, characterized in that The reagent also includes bisulfite.

4. A kit for diagnosing or assisting in the diagnosis of bladder cancer, characterized in that: The invention comprises the reagent according to any one of claims 1 to 3.

5. The kit according to claim 4, characterized in that The test samples of the kit include tissue and / or urine.

6. Use of the reagent according to any one of claims 1 to 3 in the preparation of bladder cancer diagnosis or auxiliary diagnosis products.

Citation Information

Patent Citations

  • Method of diagnosing bladder cancer

    CA2759312A1

  • Application of reagent for detecting methylation level in preparation of bladder cancer diagnostic product and bladder cancer diagnostic kit

    CN115094139A